Drug guidance
Sucroferric oxyhydroxide for treating hyperphosphataemia in patients with end-stage renal disease on dialysis
Condition
Kidney
16 September 2025
-
Published on 16 Sep 2025
Last Updated on 16 Sep 2025
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has recommended:
Sucroferric oxyhydroxide 500 mg chewable tablet for treating hyperphosphataemia in patients with end-stage renal disease on haemodialysis or peritoneal dialysis who have persistent hyperphosphataemia despite optimising treatment with calcium-based phosphate binders, or who are unable to tolerate calcium-based phosphate binders due to hypercalcaemia.
Funding status
Sucroferric oxyhydroxide 500 mg chewable tablet is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 November 2025.